Pivotal Trials in Blood Cancers Don’t Mirror Patient Populations
Clinical trials leading to drug approvals for various blood cancers have significantly underrepresented Blacks and minorities, leading to questions about the generalizability of safety and efficacy, say experts.
Medscape Medical News
source https://www.medscape.com/viewarticle/980186?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/980186?src=rss
Comments
Post a Comment